Investment Overview - The company announced the establishment of a joint venture named "Evonik Blue Biotechnology (Shandong) Co., Ltd." with Evonik (China) Investment Co., Ltd. in October 2023, where its wholly-owned subsidiary, Shandong Blue Biotechnology Co., Ltd., will exclusively produce GHS products for the joint venture through OEM processing [1][2] - The registered capital of the joint venture is RMB 37.5 million, with Shandong Blue contributing RMB 16.875 million [1] Termination of Investment - The joint venture and its Qingdao branch will be dissolved and liquidated as per the reconciliation agreement signed on July 31, 2025, due to the actual operating conditions and future business plans of both parties [2][3] - The board of directors approved the termination of the investment with a unanimous vote of 5 in favor, with no opposition or abstentions [2] Reconciliation Agreement - The reconciliation agreement includes the termination of the previous shareholder and OEM agreements, and the establishment of a liquidation team to handle the dissolution and liquidation processes [3] - The joint venture will return all intellectual property rights related to Shandong Blue, and a new OEM agreement will be signed for GHS product production [3][4] Impact on Company - The dissolution and liquidation of the joint venture are not expected to have a significant adverse impact on the company's operations or financial status, and it will not harm the interests of the company and its shareholders [5] - The new OEM agreement will allow continued cooperation in the GHS product sector without major disruptions to existing business operations [5]